共 50 条
- [21] UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphomaBRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (02) : 555 - 560Caracciolo, DanielePolera, NicolettaBelmonte, BeatriceConforti, FrancescoSignorelli, StefaniaGulino, AlessandroStaropoli, NicolettaTuccillo, Franca MariaBonelli, PatriziaJuli, GiadaGrillone, KatiaAscrizzi, SerenaCirillo, MariaMigale, LeonardoBallerini, AndreaPelizon, CristinaDi Martino, Maria TeresaTagliaferri, PierosandroRiillo, CaterinaTassone, Pierfrancesco
- [22] Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphomaHEMASPHERE, 2025, 9 (01):Stock, SophiaBucklein, Veit L.Blumenberg, ViktoriaMagno, GiuliaEmhardt, Alica-JoanaHolzem, Alessandra M. E.dos Santos, David M. CordasSchmidt, ChristianGriesshammer, StefanieFrolich, LisaKobold, Sebastianvon Bergwelt-Baildon, MichaelRejeski, KaiSubklewe, Marion
- [23] CAR T-cell therapy in refractory large B-cell lymphomaLANCET ONCOLOGY, 2018, 19 (01): : E19 - E19Stirrups, Robert
- [24] Update on CAR T-Cell Therapies for Relapsed/Refractory B-Cell LymphomasJOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 622 - 624Schuster, Stephen J.
- [25] Salvage Radiotherapy in Relapsed/ Refractory Large B-Cell Lymphoma After CAR T-Cell Therapy FailureCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S414 - S414Ababneh, HazimNg, AndreaFrigault, MatthewAbramson, JeremyJohnson, PatrickJacobson, CaronPatel, Chirayu
- [26] Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapyHAEMATOLOGICA, 2023, 108 (11) : 2972 - 2981Ababneh, Hazim S.Ng, Andrea K.Frigault, Matthew J.Abramson, Jeremy S.Johnson, Patrick ConnorJacobson, Caron A.Patel, C. G.
- [27] Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T CellsVACCINES, 2022, 10 (08)Liu, YanlongAo, KexinBao, FuxiangCheng, YiHao, YanxiaZhang, HuiminFu, ShanXu, JiaqiWu, Qiyao
- [28] Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapyBLOOD, 2024, 143 (16) : 1565 - 1575Crombie, Jennifer L.Graff, TaraFalchi, LorenzoKarimi, Yasmin H.Bannerji, RajatNastoupil, LorettaThieblemont, CatherineUrsu, RenataBartlett, NancyNachar, VictoriaWeiss, JonathanOsterson, JanePatel, KrishBrody, JoshuaAbramson, Jeremy S.Lunning, MatthewShah, Nirav N.Ayed, AyedKamdar, ManaliParsons, BenjaminCaimi, PaoloFlinn, IanHerrera, AlexSharman, JeffreyMcKenna, MarshallArmand, PhilippeKahl, BradSmith, SonaliZelenetz, AndrewBudde, Lihua ElizabethHutchings, MartinPhillips, TycelDickinson, Michael
- [29] Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphomaPATHOLOGY INTERNATIONAL, 2011, 61 (11) : 662 - 666Yamazaki, ShoFujioka, YoseiNakamura, FumihikoOta, SatoshiShinozaki, AyaYamamoto, GoKamikubo, YasuhikoNannya, YasuhitoIchikawa, MotoshiFukayama, MasashiKurokawa, Mineo
- [30] Low Mortality from COVID-19 Infection in Patients with B-Cell Lymphoma after Bispecific CD20xCD3 TherapyBLOOD, 2023, 142Kyvsgaard, Emil RamsoRiley, Anna Caroline HasselbalchClausen, Michael RoostHarslof, MadsHeftdal, Line DamNiemann, Carsten UtoftGronbaek, KirstenHutchings, MartinHusby, Simon